EMEA-000520-PIP02-13-M04
Key facts
| Invented name |
Benlysta
|
| Active substance |
belimumab
|
| Therapeutic area |
Immunology-Rheumatology-Transplantation
|
| Decision number |
P/0395/2022
|
| PIP number |
EMEA-000520-PIP02-13-M04
|
| Pharmaceutical form(s) |
Solution for injection
|
| Condition(s) / indication(s) |
Treatment of Systemic Lupus Erythematosus (SLE)
|
| Route(s) of administration |
Subcutaneous use
|
| Contact for public enquiries |
Glaxo Group Limited
E-mail: eu.paediatrics-plans@gsk.com |
| Decision type |
PM: decision on the application for modification of an agreed PIP
|